🚀 Wall Street Radar: Stocks to Watch Next Week

💼 Volume 31: 🛡️ Defensive Plays Shine: Is the Market Bracing for Impact or a Bounce? 🌩️

Portfolio updates and new positions:

⚡ AI-optimized, human-verified: Our expert team carefully selected Premium market intelligence from Finchat's data. Explore now →

T2118

The T2118 market breadth indicator has continued its significant decline throughout the week, effectively cooling off an overheated market. Currently sitting at 20.53, down from over 70.00 in recent weeks, the indicator has now reached a level that suggests a potential bounce may be forthcoming.

While historically the most reliable and sustainable market bounces occur when T2118 falls below 15.00, the current reading of 20.53 presents a reasonably attractive entry point for traders. Market conditions rarely align perfectly with ideal technical levels, and the current data suggests a short-term bounce is more likely than continued downward momentum. Supporting this view, the VIX volatility index has begun to gradually decline, potentially providing additional tailwind for a market recovery.

The current volatile environment demands a day trading mentality, which explains why our Portfolio operations remain nearly flat as we work daily to identify new opportunities. We maintain a flexible approach, as demonstrated by our recent successful trade on Valaris using 2027 calls, which yielded over 25% profit in just days. This trade wasn't added to the Portfolio due to tracking limitations in Finchat.

This example highlights the importance of adaptability. Even in down-trending markets, opportunities always exist for creative traders willing to adjust their approach.

T2108

The T2108 market breadth indicator offers more definitive signals than its T2118 counterpart, highlighting the value of monitoring both metrics daily. T2108 has established a notable double bottom at the 25.00 level, and Friday showed a modest bounce from this support zone.

• The 4% Bull-Bear Indicator reveals that bulls demonstrated strength specifically during Friday's session when the bounce initiated. However, this isolated show of buying pressure remains insufficient to confirm a sustainable trend reversal. The opening sessions of the coming week will be critical in determining whether Friday's strength represents the beginning of a meaningful recovery or merely a temporary respite.

• The 25% Bull-Bear Indicator continues to show clear bear dominance with no signs of imminent change. This longer-term metric suggests persistent downside pressure may continue to influence market conditions in the foreseeable future.

🌱 Help us help you: Coffee or Shop finds fund our progress and your gains! 🌱

Each stock on the watchlist will now have a risk grade badge next to its name, reflecting our assessment based on factors such as volatility, share float, technicals, fundamentals, ADR, and more. This badge is designed to help readers gauge the stock's risk profile, providing valuable context for making informed decisions about approaching it.

High risk: ⚠️

Medium Risk: 📊

Low Risk: 🛡️

---

🆓✨ Watchlist Essentials: Top Free Picks

HIMS: Hims & Hers Health Inc ⚠️

What they do: Telehealth platform offering personalized health and wellness products

Why watch? 📉 Following a bubble phase that resulted in a precipitous 50%+ decline over just two weeks, HIMS is exhibiting classic technical bottoming signals. Selling pressure and volume are notably diminishing, with price action suggesting an imminent breakout from a falling wedge pattern. Technical indicators point to a potential upside reversal, with the $45.00 level representing the initial target for this counter-trend rally.

Put the market on autopilot, experience the Best Platform with TC2000
Explore now →

TEM: Tempus AI Inc ⚠️

What they do: AI-powered precision medicine technology company

Why watch? 🧬 Previously highlighted in our comprehensive coverage, TEM presents another compelling entry opportunity at current levels. While not as advantageous as our initial recommendation, the risk-reward profile remains favorable for a tactical swing position. Friday's session saw the stock successfully defend the critical $47.00 support level while approaching the psychologically significant $50.00 threshold—a pivotal resistance that, once breached and sustained, could catalyze substantial upside momentum.

NBIS: Nebius Group NV ⚠️

What they do: Cloud computing and infrastructure solutions provider

Why watch? ☁️ For detailed analysis on this high-conviction selection, we refer readers to our previous comprehensive coverage. From a technical perspective, Friday's price action was particularly constructive, with the stock bouncing decisively off the $26.00 key support level. This successful defense of critical technical territory suggests accumulation dynamics are in play, potentially setting the stage for an imminent upward trajectory.

UBER: Uber Technologies 📊

What they do: Global mobility and delivery platform

Why watch?🚗 UBER continues to demonstrate exceptional relative strength against broader market indices, maintaining position above both the 10-day and 20-day exponential moving averages. The stock appears poised to challenge the $77.00 resistance level, which would represent a significant technical breakout. The weekly chart reveals a textbook hammer candlestick formation with robust support at the 10-week and 30-week simple moving averages—a confluence of technical factors suggesting institutional accumulation.

EVER: EverQuote Inc 📊

What they do: Online insurance marketplace platform

Why watch? 📈 EverQuote's stellar Q4 performance and bullish FY25 guidance catalyzed a 25% share price appreciation, underscoring the company's accelerating growth trajectory and margin expansion. Q1 projections indicate continued momentum with revenue growth exceeding 70% year-over-year. The company's pristine balance sheet features zero debt and approximately $100 million in cash reserves. Despite recent market volatility, EVER has maintained its post-earnings gap and successfully defended the $25.50 technical support level. A move above $26.00 could trigger the next leg of advance in this emerging growth story.

LMND: Lemonade Inc ⚠️

What they do: AI-powered insurance platform

Why watch?🍋 Operating within one of the market's most resilient sectors, LMND exhibits exceptional relative strength metrics versus major indices. The stock is approaching a critical technical inflection point at the $38.00 resistance level. A decisive breach above this threshold could signal the initiation of a new uptrend phase, potentially unlocking significant upside potential as momentum-driven capital flows accelerate.

CDXC: ChromaDex Corporation ⚠️

What they do: Bioscience company focused on nicotinamide riboside and NAD+ technologies

Why watch?🧪 CDXC recently delivered a transformative earnings report, posting record Q4 2024 revenues of $29.1 million—representing 37% year-over-year growth. The company achieved net income of $7.2 million for the quarter, contributing to full-year profitability of $8.6 million—a remarkable turnaround from prior-year losses. With $44.7 million in cash and zero debt, the balance sheet provides substantial operational flexibility. Technically, the stock is consolidating just below significant resistance at $7.80, with recent pullbacks occurring on diminishing volume—a classic accumulation pattern. A breakout above $7.80 accompanied by increasing volume could trigger a second wave of upside momentum.

💎📈 Watchlist Elite: Premium Market Movers

Each selection undergoes rigorous financial analysis, technical evaluation, and strategic assessment - delivering institutional-grade research.

Every week, we showcase one complete premium analysis at no cost - letting you experience firsthand the depth and quality that sets Elite research apart.

INMB: INmune Bio Inc ⚠️

What they do: Clinical-stage biotechnology company focused on neuroinflammation and cancer immunotherapy

Why watch? 🧠 INmune Bio's dual-asset portfolio presents multiple shots on goal, with XPro targeting neuroinflammation in Alzheimer's disease and treatment-resistant depression, while INKmune addresses prostate cancer through novel immunotherapy mechanisms.

XPro has demonstrated promising biomarker results in Alzheimer's trials, potentially outperforming existing treatments and attracting significant pharmaceutical industry interest. The fully enrolled Phase 2 Alzheimer's trial represents a pivotal catalyst, with topline data expected in May-June 2025.

Technical analysis reveals constructive patterns across multiple timeframes (daily, weekly, and monthly), with $7.27 established as a key support level. Near-term resistance between $8.00-$8.30 represents the immediate hurdle, with successful clearance potentially facilitating a retest of recent highs above $10.00 per share.